Study on the Safety of Insulin Degludec and Insulin Aspart Injection Combined with Acarbose in the Treatment of Type 2 Diabetes Mellitus
Objective To study the safety and efficacy of insulin degludec and insulin aspart injection combined with acarbose in the treatment of type 2 diabetes mellitus.Methods Totally 72 type 2 diabetes mellitus patients who were diagnosed and treated in our hospital from May 2022 to July 2023 were selected as the research objects. Using the random number table method,patients were divided into routine group (n=36) and test group (n=36). In the routine group,patients were treated with insulin degludec and insulin aspart injection,while in the test group,patients were treated with acarbose on the basis of the routine group. The clinical efficacy,blood glucose indexes[glycosylated hemoglobin (HbA1c),fasting blood glucose (FPG)],blood lipid indexes[triglyceride (TG),total cholesterol (TC)],serum feeding inhibitor 1 (Nesfatin-1),adiponectin (ADP) levels and incidence of adverse reactions were compared between the two groups.Results Compared with the routine group (83.33％),the total effective rate of treatment in the test group (97.22％) was higher (P<0.05). After treatment,HbA1c and FPG in the two groups were lower than those before treatment,and compared with the routine group,those in the test group were lower (P<0.05). After treatment,TG and TC in the two groups were lower than those before treatment,and compared with the routine group,those in the test group were lower (P<0.05). After treatment,Nesfatin-1 in the two groups was lower than that before treatment,ADP was higher than that before treatment,and compared with the routine group,Nesfatin-1 in the test group was lower,ADP was higher (P<0.05). Compared with the routine group (19.44％),the incidence of adverse reactions in the test group (8.33％) was lower (P<0.05).Conclusion The combination of insulin degludec and insulin aspart injection combined with acarbose in patients with type 2 diabetes mellitus can improve the total effective rate,improve blood glucose and blood lipid indexes,reduce the level of nesfatin-1,and increase the level of ADP. It is a safe and effective combination therapy.
Insulin degludec and insulin aspart injectionAcarboseType 2 diabetes mellitusSafety
万方数据
维普
